ZhouEY, LinZ, YangY. 2015. HABP2 mutation and nonmedullary thyroid cancer. N Engl J Med, 373:2084–2085.
3.
SponzielloM, DuranteC, FilettiS. 2015. HABP2 mutation and nonmedullary thyroid cancer. N Engl J Med, 373:2085–2086.
4.
TomsicJ, HeH, de la ChapelleA. 2015. HABP2 mutation and nonmedullary thyroid cancer. N Engl J Med, 373:2086.
5.
ZhaoX, LiX, ZhangX. 2015. HABP2 mutation and nonmedullary thyroid cancer. N Engl J Med, 373:2084.
6.
SahasrabudheR, StultzJ, WilliamsonJ, LottP, EstradaA, BohorquezM, PallesC, Polanco-EcheverryG, JaegerE, MartinL, Magdalena EcheverryM, TomlinsonI, Carvajal-CarmonaLG; TCUKIN. 2016. The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. J Clin Endocrinol Metab, 101:1098–1103.
7.
TomsicJ, FultzR, LiyanarachchiS, HeH, SenterL, de la ChapelleA. 2016. HABP2 G534E variant in papillary thyroid carcinoma. PLoS One, 11:e0146315.
8.
AlzahraniAS, MuruganAK, QasemE, Al-HindiHN. 2016. HABP2 gene mutations do not cause familial or sporadic non-medullary thyroid cancer in a highly inbred Middle Eastern population. Thyroid, 26:667–671.
